Abbott's troubled baby formula Michigan plant to reopen In 1-2 weeks
Abbott's troubled baby formula Michigan plant to reopen In 1-2 weeks
$Abbott Laboratories(ABT.US)$ and the FDA are reportedly on track to reopen the company's Sturgis, Michigan, baby formula manufacturing plant within one or two weeks, FDA Commissioner Robert Califf said.
Abbott, the biggest U.S. supplier of powder infant formula, including Similac, agreed with the FDA on the steps needed to resume production at the manufacturing plant.
"I think we are on track to get it open within the next week to two weeks, most likely at the outer bound two weeks," Califf told lawmakers at a U.S. House of Representatives Appropriations Subcommittee hearing.
The company initiated a recall of its infant formula products. In February, it closed the plant after reports of serious bacterial infections in four infants, which worsened due to the pandemic supply chain issues.
Price Action: ABT shares were up 1.17% at $113.75 during the premarket session on the last check Friday.
$雅培(ABT.US)$FDA專員羅伯特·卡里夫表示，據報道，FDA將在一到兩週內重新開放該公司位於密歇根州斯特吉斯的嬰兒配方奶粉製造廠。
雅培是包括Similac在內的美國最大的嬰兒配方奶粉供應商，該公司與FDA就恢復製造廠生產所需的步驟達成了一致。
卡里夫在美國眾議院撥款委員會的聽證會上對議員們説：“我認為我們有望在未來一到兩週內將其投入使用，最有可能的是在外圍兩週內開放。”
該公司啟動了對其嬰兒配方奶粉產品的召回。今年2月，在有報道稱四名嬰兒受到嚴重細菌感染後，該公司關閉了這家工廠，由於大流行的供應鏈問題，情況惡化。
價格行動：上週五最後一次開盤前交易時段，ABT股價上漲1.17%，至113.75美元。